Matthias H Tschöp Selected Research

Hyperglycemia

10/2018	Chronic d-serine supplementation impairs insulin secretion.
10/2018	Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.
8/2017	The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
8/2015	miR-184 Regulates Pancreatic β-Cell Function According to Glucose Metabolism.
5/2013	Fibroblast growth factor 21 mediates specific glucagon actions.
12/2012	Targeted estrogen delivery reverses the metabolic syndrome.
1/2012	Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
7/2010	Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity.
5/2010	Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthias H Tschöp Research Topics

Disease

108	Obesity 04/2024 - 01/2003
83	Body Weight (Weight, Body) 04/2024 - 08/2003
33	Insulin Resistance 01/2023 - 10/2003
28	Type 2 Diabetes Mellitus (MODY) 11/2023 - 10/2003
27	Weight Loss (Weight Reduction) 11/2023 - 08/2007
16	Glucose Intolerance 10/2018 - 11/2007
15	Inflammation (Inflammations) 01/2021 - 10/2007
12	Metabolic Diseases (Metabolic Disease) 04/2024 - 12/2010
10	Hyperphagia (Overeating) 01/2017 - 04/2006
9	AIDS-Related Complex (ARC) 11/2022 - 06/2008
9	Hyperglycemia 10/2018 - 05/2010
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/2017 - 10/2007
8	Dyslipidemias (Dyslipidemia) 01/2023 - 05/2009
6	Weight Gain 01/2019 - 08/2007
5	Neoplasms (Cancer) 01/2018 - 08/2007
5	Cachexia 04/2017 - 07/2008
4	Atherosclerosis 01/2023 - 01/2011
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 01/2011
4	Anorexia 01/2019 - 09/2005
3	Nausea 01/2023 - 12/2016
3	Non-alcoholic Fatty Liver Disease 01/2021 - 07/2012
3	Gliosis 02/2018 - 08/2010
3	Anorexia Nervosa 01/2013 - 05/2011
3	Sepsis (Septicemia) 12/2010 - 07/2009
2	Hypertension (High Blood Pressure) 11/2023 - 12/2016
2	Hypoxia (Hypoxemia) 01/2021 - 01/2017
2	Fatty Liver 01/2019 - 10/2016
2	Ketosis 01/2018 - 01/2011

Drug/Important Bio-Agent (IBA)

57	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 08/2003
32	GhrelinIBA 01/2018 - 01/2003
27	Glucagon-Like Peptide 1 (GLP 1)IBA 03/2024 - 05/2009
24	Peptides (Polypeptides)IBA 03/2024 - 02/2006
22	Insulin (Novolin)FDA Link 01/2023 - 08/2003
21	Hormones (Hormone)IBA 04/2024 - 09/2005
18	LeptinIBA 03/2024 - 04/2006
16	LipidsIBA 01/2020 - 11/2007
10	Glucagon (Glukagon)FDA Link 01/2020 - 10/2009
9	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 01/2021 - 02/2006
9	CarbohydratesIBA 01/2018 - 02/2009
8	fibroblast growth factor 21IBA 01/2023 - 06/2012
8	Triglycerides (Triacylglycerol)IBA 01/2020 - 03/2008
8	Ghrelin ReceptorsIBA 01/2014 - 03/2008
7	IncretinsIBA 04/2024 - 10/2013
7	CholesterolIBA 01/2020 - 08/2011
6	gastric inhibitory polypeptide receptorIBA 03/2024 - 08/2008
5	Glucagon Receptors (Glucagon Receptor)IBA 04/2024 - 10/2009
5	Blood Glucose (Blood Sugar)IBA 01/2023 - 05/2010
5	MelanocortinsIBA 01/2023 - 11/2007
4	Exenatide (Byetta)FDA Link 04/2024 - 06/2012
4	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2023 - 09/2012
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2011
4	Glucagon-Like Peptide-1 ReceptorIBA 01/2019 - 05/2009
4	EnzymesIBA 01/2017 - 11/2008
4	salicylhydroxamic acid (SHAM)IBA 12/2016 - 01/2012
4	Estrogens (Estrogen)FDA Link 11/2016 - 08/2008
4	Dietary Fats (Dietary Fat)IBA 04/2014 - 11/2007
4	AcyltransferasesIBA 01/2013 - 05/2011
3	Leptin ReceptorsIBA 03/2024 - 09/2012
3	LDL Receptors (LDL Receptor)IBA 01/2023 - 11/2007
3	Glial Fibrillary Acidic ProteinIBA 11/2022 - 10/2017
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2018
3	Sucrose (Saccharose)IBA 01/2021 - 12/2008
3	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2020 - 10/2018
3	celastrolIBA 03/2019 - 11/2018
3	Liraglutide FDA Link 01/2019 - 03/2015
3	GlucocorticoidsIBA 01/2018 - 02/2012
3	Peptide Hormones (Polypeptide Hormones)IBA 01/2018 - 12/2010
3	Dietary Carbohydrates (Carbohydrate, Dietary)IBA 01/2018 - 01/2011
3	Metformin (Glucophage)FDA LinkGeneric 01/2018 - 01/2016
3	RimonabantIBA 12/2015 - 11/2008
3	acyl-ghrelinIBA 01/2014 - 05/2011
3	Fatty Acids (Saturated Fatty Acids)IBA 10/2012 - 11/2009
3	Growth Hormone (Somatotropin)IBA 09/2012 - 02/2009
3	NeuropeptidesIBA 12/2010 - 02/2006
2	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 04/2024 - 08/2017
2	tirzepatideIBA 01/2023 - 01/2023
2	Thyroid HormonesIBA 12/2022 - 10/2016
2	Blood Proteins (Serum Proteins)IBA 03/2021 - 01/2021
2	MicellesIBA 03/2021 - 01/2020
2	Dual-Specificity PhosphatasesIBA 11/2020 - 01/2017
2	Uncoupling Protein 1IBA 01/2020 - 01/2020
2	Dimethylphenylpiperazinium IodideIBA 01/2020 - 10/2018
2	Apolipoproteins E (ApoE)IBA 01/2019 - 01/2008
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 06/2007
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 02/2012
2	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2019 - 02/2012
2	CalcineurinIBA 02/2018 - 11/2015
2	AcidsIBA 01/2018 - 09/2011
2	Mechanistic Target of Rapamycin Complex 1IBA 01/2018 - 12/2013
2	OsteopontinIBA 01/2018 - 10/2007
2	Anti-Obesity Agents (Antiobesity Drugs)IBA 10/2017 - 09/2012
2	AntioxidantsIBA 01/2017 - 12/2013
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2016 - 01/2012

Therapy/Procedure

23	Therapeutics 04/2024 - 06/2006
9	Bariatric Surgery 04/2024 - 01/2013
7	Drug Therapy (Chemotherapy) 04/2024 - 09/2013
5	Gastric Bypass (Roux-en-Y Gastric Bypass) 02/2014 - 08/2007
4	Glycemic Control 01/2019 - 01/2015
3	Caloric Restriction 11/2012 - 08/2007
2	Subcutaneous Injections 01/2023 - 02/2011